RT Journal Article
SR Electronic
T1 A highly effective reverse-transcription loop-mediated isothermal amplification (RT-LAMP) assay for the rapid detection of SARS-CoV-2 infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.30.20142935
DO 10.1101/2020.06.30.20142935
A1 Fowler, Veronica L.
A1 Armson, Bryony
A1 Gonzales, Jose L.
A1 Wise, Emma L.
A1 Howson, Emma L. A.
A1 Vincent-Mistiaen, Zoe
A1 Fouch, Sarah
A1 Maltby, Connor J.
A1 Grippon, Seden
A1 Munro, Simon
A1 Jones, Lisa
A1 Holmes, Tom
A1 Tillyer, Claire
A1 Elwell, Joanne
A1 Sowood, Amy
A1 de Peyer, Oliver
A1 Dixon, Sophie
A1 Hatcher, Thomas
A1 Patrick, Helen
A1 Laxman, Shailen
A1 Walsh, Charlotte
A1 Andreou, Michael
A1 Morant, Nick
A1 Clark, Duncan
A1 Moore, Nathan
A1 Houghton, Rebecca
A1 Cortes, Nicholas
A1 Kidd, Stephen P.
YR 2020
UL http://medrxiv.org/content/early/2020/10/25/2020.06.30.20142935.abstract
AB The COVID-19 pandemic has illustrated the importance of simple, rapid and accurate diagnostic testing. This study describes the validation of a new rapid SARS-CoV-2 RT-LAMP assay for use on extracted RNA or directly from swab offering an alternative diagnostic pathway that does not rely on traditional reagents that are often in short supply during a pandemic.Analytical specificity (ASp) of this new RT-LAMP assay was 100% and analytical sensitivity (ASe) was between 1×101 and 1×102 copies per reaction when using a synthetic DNA target. The overall diagnostic sensitivity (DSe) and specificity (DSp) of RNA RT-LAMP was 97% and 99% respectively, relative to the standard of care rRT-PCR. When a CT cut-off of 33 was employed, above which increasingly evidence suggests there is a low risk of patients shedding infectious virus, the diagnostic sensitivity was 100%. The DSe and DSp of Direct RT-LAMP (that does not require RNA extraction) was 67% and 97%, respectively. When setting CT cut-offs of ≤33 and ≤25, the DSe increased to 75% and 100%, respectively, time from swab-to-result, CT < 25, was < 15 minutes.We propose that RNA RT-LAMP could replace rRT-PCR where there is a need for increased sample throughput and Direct RT-LAMP as a near-patient screening tool to rapidly identify highly contagious individuals within emergency departments and a care homes during times of increased disease prevalence; ensuring negative results still get laboratory confirmation.HighlightsNovel rapid RT-LAMP assay with diagnostic sensitivity and specificity of 97% and 99%Development of an RNA extraction free direct detection method for SARS-CoV-2Use case modelling for rapid Direct RT-LAMP in near-patient clinical practiceDeveloping diversity of testing modalities within a diagnostic laboratory during a pandemic.Competing Interest StatementAuthors MA, NM, SL, and CW are directors/employees of Optisense Limited and GeneSys Biotech Limited. After providing initial reagents free of charge they played no further part in study design, data collection or analysis.Funding StatementInitial reagents were provided free of charge from Optigene then further study work was funded by the Microbiology Department at Hampshire Hospitals NHS Foundation Trust.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Hospital ethics committee declared exemption for this service improvement study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available as required at the end of the document.